Immutep LtdASX: IMM

Encouraging Disease-Free Survival in Phase II Sarcoma Trial

· Issued by Immutep Ltd via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Higher levels of tumor-infiltrating lymphocytes and treatment-related hyalinisation were associated with improved survival outcomes. The findings support the potential of efti-based combination therapy and indicate a strong rationale for further clinical evaluation.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma • Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month disease-free survival (DFS) of 81.1% in...

Immutep Ltd on 6ix

Earlier from Immutep

All Immutep news releases